Patients were successfully implanted with MINIject at the IOES (Institute of Eye Surgery), Mullingar, by Anish Dhital
iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces that the first patients in Ireland have been implanted with MINIject, expanding the commercial rollout of the Company’s minimally-invasive glaucoma surgery (MIGS) device across Europe.
Glaucoma is the leading cause of blindness in Ireland, with the incidence of the condition expected to rise by 33% over the coming decade. Patients in Ireland with open-angle glaucoma will now have available to them, a powerful new treatment option and will be able to benefit from the many advantages offered by MINIject compared to traditional treatment methods. Currently the only commercially available supraciliary MIGS implant, MINIject has demonstrated meaningful and sustained performance, combined with a favorable safety profile.
Patients were successfully implanted with MINIject at the IOES (Institute of Eye Surgery), Mullingar, by Anish Dhital. This follows iSTAR Medical’s recent expansion of MINIject into other European countries including Sweden and Norway.
Anish Dhital, Cataract and Glaucoma Specialist at the IOES (Mullingar) said: “The successful implantation of iSTAR Medical’s MIGS device MINIject marks another milestone in the advancement of glaucoma treatment in Ireland. Our ability to offer a new glaucoma implant that can significantly and safely lower IOP, and target a new drainage pathway will benefit patients – enabling them to reduce reliance on medication and preserve their vision for longer.”
Michel Vanbrabant, CEO of iSTAR Medical, commented: “It is both exciting and validating that one of Ireland’s largest network of eye clinics to offer all ocular sub-specialties, the IOES, has engaged with our technology and we want to thank the clinicians for their commitment. The continuation of our commercial rollout of MINIject with the recent implantations in Ireland represents iSTAR Medical’s mission to preserve the vision of glaucoma patients around the world. We are proud to be providing more patients with a safe and minimally-invasive treatment for open-angle glaucoma, giving them a sustained and prolonged treatment option. As we continue with our global expansion, we look forward to making MINIject more widely available to patients.”
Source: Company Press Release